Traws Pharma Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Stockholders’ Equity (Deficit)
Consolidated Statement of Stockholders’ Equity (Deficit) (unaudited)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Month Periods Ended March 31, 2024 and 2023 | |||||||||||||||||
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · other · · · | |||||||||||||||||
| · · Common Stock · · Paid in · · Accumulated · · comprehensive · · · | |||||||||||||||||
| · Shares · Amount · Capital · deficit · (loss) income · Total | |||||||||||||||||
| Balance at December 31, 2023 | | 21,003,409 | | $210,000 | | $493,116,000 | | $(482,631,000) | | $(23,000) | | $10,672,000 | |||||
| Net loss | — | | — | | — | | (4,983,000) | | — | | (4,983,000) | ||||||
| Other comprehensive loss | — | | — | | — | | — | | (7,000) | | (7,000) | ||||||
| Stock-based compensation | | — | | — | | 333,000 | | — | | — | | 333,000 | |||||
| Shares issued for vested restricted stock units | 82,526 | | 1,000 | | (1,000) | | — | | — | | — | ||||||
| Balance at March 31, 2024 | | 21,085,935 | | $211,000 | | $493,448,000 | | $(487,614,000) | | $(30,000) | | $6,015,000 | |||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2022 | | 20,925,992 | | $209,000 | | $491,816,000 | | $(463,683,000) | | $(33,000) | | $28,309,000 | |||||
| Net loss | — | | — | | — | | (5,775,000) | | — | | (5,775,000) | ||||||
| Other comprehensive loss | — | | — | | — | | — | | 6,000 | | 6,000 | ||||||
| Exercise of stock options | | — | | — | | — | | — | | — | | — | |||||
| Stock-based compensation | — | | — | | 336,000 | | — | | — | | 336,000 | ||||||
| Shares issued for vested restricted stock units | | 43,567 | | 1,000 | | (1,000) | | — | | — | | — | |||||
| Balance at March 31, 2023 | | 20,969,559 | | $210,000 | | $492,151,000 | | $(469,458,000) | | $(27,000) | | $22,876,000 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.